NCT01856868View on ClinicalTrials.gov

Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Becker Muscular Dystrophy
Interventions
DRUG

(-)-epicatechin

purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.

Trial Locations (1)

95817

University of California, Davis, Sacramento

Sponsors
All Listed Sponsors
collaborator

Cardero Therapeutics, Inc.

INDUSTRY

lead

Craig McDonald, MD

OTHER